Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias
FILTRAR POR:
559 ARTÍCULOS , VIENDO DEL 1 AL 15
The Current Evidence for the Therapeutic Role of Curcumin in Alzheimer's Disease
Bland AR, Ashton JC, Kamal MA, Sahebkar A.
CNS Neurol Disord Drug Targets. 2023;22(3):318-320. doi: 10.2174/1871527321666220119105836.
Impact of the Cannabinoid System in Alzheimer's Disease
Li S, Huang Y, Yu L, Ji X, Wu J.
Curr Neuropharmacol. 2023;21(3):715-726. doi: 10.2174/1570159X20666220201091006.
Selenium-Derivative Compounds: A Review of New Perspectives in the Treatment of Alzheimer's Disease
Barbosa FAR, Canto RFS, Teixeira KF, de Souza AS, de Oliveira AS, Braga AL.
Curr Med Chem. 2023;30(6):689-700. doi: 10.2174/0929867329666220224161454.
Epigenetic Modifications by Estrogen and Androgen in Alzheimer's Disease
Kumar R, Fatima F, Yadav G, Singh S, Haldar S, Alexiou A, Ashraf GM.
CNS Neurol Disord Drug Targets. 2023;22(1):6-17. doi: 10.2174/1871527321666220225110501.
Martins GL, Ferreira CN, Palotás A, Rocha NP, Reis HJ.
Curr Neuropharmacol. 2023;21(2):202-212. doi: 10.2174/1570159X20666220327215245.
Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer's Disease
Unnisa A, Greig NH, Kamal MA.
Curr Med Chem. 2023;30(3):255-270. doi: 10.2174/0929867329666220328125206.
Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review
Mathew A, Balaji E V, Pai SRK, Kishore A, Pai V, Pemmireddy R, K S C.
CNS Neurol Disord Drug Targets. 2023;22(2):255-275. doi: 10.2174/1871527321666220401124719.
Alasmari F, Alotaibi FM, Al-Qahtani WS, AlAsmari AF, Alqahtani F.
CNS Neurol Disord Drug Targets. 2023;22(5):736-744. doi: 10.2174/1871527321666220418125057.
Berberine: Is it a Promising Agent for Mental Disorders Treatment?
Shayganfard M.
Curr Mol Pharmacol. 2023;16(3):307-320. doi: 10.2174/1874467215666220509213122.
The Involvement of Melatonin and Tasimelteon against Alzheimer's Disease
Ravikumar M, Mohan S, Velpandian C.
Curr Drug Saf. 2023;18(3):284-296. doi: 10.2174/1574886317666220517125644.
Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease
Sharma P, Babbar R, Sharma T, Madaan P, Arora S, Badavath VN.
Mini Rev Med Chem. 2023;23(1):53-66. doi: 10.2174/1389557522666220524090354.
DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease
de Souza MM, Cenci AR, Teixeira KF, Machado V, Mendes Schuler MCG, Gonçalves AE, Paula Dalmagro A, André Cazarin C, Gomes Ferreira LL, de Oliveira AS, Andricopulo AD.
Curr Med Chem. 2023;30(6):669-688. doi: 10.2174/0929867329666220620162018.
Anticholinesterase Agents For Alzheimer's Disease Treatment: An Updated Overview
Llanes LC, Kuehlewein I, França IV, da Silva LV, da Cruz Junior JW.
Curr Med Chem. 2023;30(6):701-724. doi: 10.2174/0929867329666220803113411.
Abu-El-Rub E, Khasawneh RR, Almahasneh FA, Aloud BM, Zegallai HM.
Curr Stem Cell Res Ther. 2023;18(5):580-594. doi: 10.2174/1574888X17666220831105257.
Genetic Causes of Alzheimer's Disease and the Neuroprotective Role of Melatonin in its Management
Sundram S, Malviya R, Awasthi R.
CNS Neurol Disord Drug Targets. 2023;22(9):1302-1312. doi: 10.2174/1871527321666220901125730.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.